Suven Ropanicant Phase-2b trial for Major Depressive Disorder achieves 100 percent enrollment ahead of schedule

Suven anticipate topline efficacy and safety results in May 2026.

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-12-11 08:46 GMT | Update On 2025-12-11 08:46 GMT

Hyderabad: Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on discovering and developing treatments for Central Nervous System (CNS) disorders, has announced that its Phase-2b clinical trial of Ropanicant, a nicotinic α4β2 receptor antagonist for treating Major Depressive Disorder (MDD) has successfully achieved its 100% patient enrolment target for anticipated randomization, more than two months ahead of schedule. This study is conducted exclusively in USA.

The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA for a treatment duration of six weeks. The study will evaluate the efficacy and safety of Ropanicant in patients with MDD, compared to placebo, in improving symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS).

In less than six months from study initiation, the trial successfully reached its full enrollment target of 195 patients for randomization.

Safety data from the study is being monitored continuously, with no significant concerns observed to date.

Suven anticipate topline efficacy and safety results in May 2026.

“I am deeply grateful to the patients, caregivers, investigators, and our clinical development team for their exceptional commitment in helping us achieve this milestone so rapidly. Together, we are advancing an important scientific effort to evaluate the potential of Ropanicant in patients with MDD. This collective progress moves us closer to delivering new therapeutic options that can meaningfully improve patient lives,” said Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences.

“The milestone represents another exciting step forward as we advance the investigationof Ropanicant in patients with MDD. We reached 100% patient enrolment milestone approximately six months from study initiation, reflecting the high interest from patients and physicians in a potential treatment option with novel mechanism of action. If positive, ropanicant has a potential to transform the lives of people affected by MDD and those around them. Our focus remains on advancing the program efficiently, and we look forward to presenting outcome of this trial by May 2026” said Dr. Ramakrishna Nirogi, President and CSO of Suven Life Sciences.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Suven Ropanicant Phase-2b trial for Major Depressive Disorder achieves 100 percent enrollment ahead of schedule

Suven anticipate topline efficacy and safety results in May 2026.

Similar News

Medicines Aren't Groceries: AIOCD Urges PM to Shut Down Illegal Online Pharmacies After Blinkit Sting

Govt Panel Proposes Separate Licensing System for Bulk Drugs and Excipients Wholesalers

Alembic Pharma wins USFDA nod for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension

Boehringer Ingelheim Jascayd receives regulatory approval for progressive pulmonary fibrosis in China

GSK risvutatug rezetecan gets USFDA Orphan Drug Designation for lung cancer

Kerala Blocks 17 Faulty Medicines Including Rabeprazole, Ciprofloxacin After Counterfeit Seizure

Indian Pharma Market Posts 9% Surge in November Even as Volumes Stay Flat: PharmaTrac